Related references
Note: Only part of the references are listed.Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients
Anne-Genevieve Marcelin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model
Stephen R. Yant et al.
NATURE MEDICINE (2019)
HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors
Paul Spearman
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
Beata Nowicka-Sans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
HIV-1 assembly, release and maturation
Eric O. Freed
NATURE REVIEWS MICROBIOLOGY (2015)
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins
Zandrea Ambrose et al.
VIROLOGY (2014)
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
Nicolas A. Margot et al.
ANTIVIRAL RESEARCH (2012)
Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat
Nicolas A. Margot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Role of Gag in HIV Resistance to Protease Inhibitors
Francois Clavel et al.
VIRUSES-BASEL (2010)
Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss
Elisabeth Dam et al.
PLOS PATHOGENS (2009)
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism
Monique Nijhuis et al.
PLOS MEDICINE (2007)
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)
Catherine S. Adamson et al.
JOURNAL OF VIROLOGY (2006)
PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing
F Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors
H Gatanaga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
HCF Cote et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
